PRISM BioLab Co. LTD (JP:206A)
:206A
Top Page
PRISM BioLab Co. LTD
(206A)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥170.00
▲(6.25% Upside)
Action:ReiteratedDate:03/17/26
The score is weighed down primarily by weak financial performance—persistent losses and worsening cash flow/funding risk—despite strong recent revenue growth and no debt. Technicals are moderately supportive with a mild positive momentum backdrop, but valuation remains unattractive due to negative earnings and no dividend yield.
Positive Factors
Debt-free balance sheet
A debt-free capital structure materially lowers solvency risk and preserves strategic optionality for a pre-commercial biotech. It supports continued R&D spending, partner-friendly licensing deals, or time to raise capital on better terms, reducing near-term liquidity pressure.
Negative Factors
Persistent net losses
Multi-year operating and net losses erode retained equity and limit reinvestment capacity. Persistent negative profitability means the company must continually secure external funding or partnerships to sustain R&D and operations, raising execution and dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free capital structure materially lowers solvency risk and preserves strategic optionality for a pre-commercial biotech. It supports continued R&D spending, partner-friendly licensing deals, or time to raise capital on better terms, reducing near-term liquidity pressure.
Read all positive factors
PRISM BioLab Co. LTD (206A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.09B
Dividend YieldN/A
Average Volume (3M)2.26M
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS GrowthN/A
CountryJP
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.74
Shares Outstanding36,934,000
10 Day Avg. Volume1,556,930
30 Day Avg. Volume2,256,993
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.27
Price to Sales (P/S)9.06
P/FCF Ratio-4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PRISM BioLab Co. LTD Business Overview & Revenue Model
Company Description
PRISM BioLab Co., LTD (206A) is a biotechnology company specializing in the discovery and development of small molecule drugs. The company focuses on innovative structural biology techniques to develop novel therapeutic agents targeting a range of...
How the Company Makes Money
PRISM BioLab primarily generates revenue through partnering/licensing arrangements with pharmaceutical and biotechnology companies around its drug discovery capabilities and pipeline programs. Typical revenue sources in this model include (1) upfr...
PRISM BioLab Co. LTD Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 677.33M | 305.62M | 112.93M | 554.40M |
| Gross Profit | 269.76M | 160.54M | 80.31M | 535.14M |
| EBITDA | -831.28M | -1.05B | -488.13M | 67.89M |
| Net Income | -833.70M | -1.05B | -526.91M | 72.96M |
Balance Sheet | ||||
| Total Assets | 3.09B | 4.53B | 1.21B | 1.74B |
| Cash, Cash Equivalents and Short-Term Investments | 2.92B | 4.39B | 1.13B | 1.69B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 376.86M | 1.03B | 63.41M | 65.23M |
| Stockholders Equity | 2.71B | 3.50B | 1.15B | 1.67B |
Cash Flow | ||||
| Free Cash Flow | -1.53B | -61.55M | -548.40M | 97.25M |
| Operating Cash Flow | -1.47B | 150.14M | -513.81M | 102.96M |
| Investing Cash Flow | -69.01M | -244.19M | -40.38M | -7.87M |
| Financing Cash Flow | 33.59M | 3.37B | 0.00 | 110.87M |
PRISM BioLab Co. LTD Technical Analysis
Positive
160.00
Price Trends
194.64
Negative
180.55
Positive
186.79
Positive
Market Momentum
-3.40
Positive
50.14
Neutral
42.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:206A, the sentiment is Positive. The current price of 160 is below the 20-day moving average (MA) of 192.10, below the 50-day MA of 194.64, and below the 200-day MA of 186.79, indicating a neutral trend. The MACD of -3.40 indicates Positive momentum. The RSI at 50.14 is Neutral, neither overbought nor oversold. The STOCH value of 42.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:206A.
PRISM BioLab Co. LTD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ¥28.14B | -34.16 | ― | ― | -5.65% | -469.19% | |
58 Neutral | ¥7.70B | 59.41 | ― | 1.24% | -14.78% | -95.53% | |
56 Neutral | ¥17.41B | 120.78 | ― | ― | 1.24% | -33.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ¥11.77B | -8.14 | ― | ― | -42.49% | -2.37% | |
48 Neutral | ¥7.09B | -5.04 | ― | ― | ― | ― | |
45 Neutral | ¥18.99B | -11.30 | ― | ― | ― | 11.34% |
* Healthcare Sector Average
JP:206A
PRISM BioLab Co. LTD
192.00
-88.00
-31.43%
JP:4599
StemRIM Inc.
303.00
-14.00
-4.42%
JP:4880
CellSource Co., Ltd.
388.00
-354.54
-47.75%
JP:4978
ReproCELL Inc.
183.00
36.00
24.49%
JP:7774
Japan Tissue Engineering Co., Ltd.
693.00
236.00
51.64%
JP:7776
CellSeed Inc.
306.00
-252.00
-45.16%
PRISM BioLab Co. LTD Corporate Events
PRISM BioLab and Receptor.AI Team Up on AI-Driven Small-Molecule Drug Discovery
Mar 12, 2026
PRISM BioLab and Receptor.AI have signed a drug discovery collaboration to build an integrated, AI-navigated, physics-guided platform for designing orally available small molecules against intracellular protein–protein interactions, membrane...
PRISM BioLab Widens Quarterly Losses and Withholds Full-Year Guidance
Feb 13, 2026
PRISM BioLab reported first-quarter revenue of ¥132 million for the fiscal year ending September 30, 2026, a modest year-on-year increase, but remained in the red with an operating loss of ¥284 million and a net loss of ¥285 million...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.